What the health care investor pool in the Netherlands actually looks like
If you're building a health care startup in the Netherlands, the good news is there's a real, active investor base to go after. Health care investors based in the Netherlands skew heavily toward venture capital and private equity funds rather than individual angels. Roughly seven in ten are tagged as venture capital, and a similar share are tagged private equity, with plenty of overlap between the two. Angel individuals make up a much smaller slice of the group.
That split isn't random. Health care is capital-intensive in a way most consumer or B2B software isn't. Clinical trials, regulatory approval, and manufacturing all cost real money before you see meaningful revenue, so it takes a fund with real dry powder to stay in for the ride. If you're pitching a digital health app with a short path to revenue, that's a different conversation than if you're pitching a Class II medical device that still needs CE marking. Know which conversation you're having before you start reaching out.
The stage gap: strong at seed, thin at Series A
Seed is by far the most common stage among health care investors here, followed by early stage venture and pre-seed. That part isn't surprising. What is worth knowing: Series A activity among this group is no bigger than Series B, and if anything trails slightly behind it. Across the Netherlands as a whole, Series A investors outnumber Series B investors by a comfortable margin, so this is a real inversion specific to health care, not just how Dutch investing works in general.
In practice, that means the jump from pre-seed to a proper Series A round is a tighter squeeze for Dutch health care founders than it is for founders in most other sectors. The investors who do make it to Series B tend to stay in for bigger, more committed rounds, which tracks with how long clinical and regulatory timelines run. If you're heading into a Series A raise, plan for a longer process and a smaller pool of leads than a SaaS founder would face, and start those conversations earlier than you think you need to.
Where these investors are based
Amsterdam and the wider North Holland region host the largest share of health care investors in the country by a wide margin. South Holland, home to The Hague and Rotterdam, and North Brabant, home to Tilburg and Eindhoven, each carry a meaningful second-tier presence. Investors further out, in Gelderland and Utrecht, are fewer but still active.
Don't read too much into geography here, though. Most of these funds invest nationally, not just in their home city, so a founder in Groningen or Maastricht isn't shut out of an Amsterdam-based fund's pipeline. Location matters more for in-person networking (accelerator demo days, health tech meetups, university spinout events) than it does for who's actually willing to write you a check.
What Dutch health care investors actually look for
Two things separate a strong pitch from a weak one in this category. First, a credible regulatory path. If your product needs CE marking under the EU's Medical Device Regulation, investors want to see that you understand what that process involves and how long it realistically takes, not just that you've heard of it. Second, a real answer to who pays. Dutch health care runs on a mix of statutory insurers (zorgverzekeraars) and hospital budgets, and an investor will want to know whether your product gets reimbursed, purchased directly, or sold as a cost-saving tool to a hospital's own budget. Vague answers here read as a founder who hasn't done the homework.
On deal terms, the numbers don't really change by sector: angel investors here typically write checks between $25,000 and $500,000, while venture and private equity investors, who make up most of this group, start much larger, usually from $2 million up. Early-stage dilution generally runs 15% to 25% per round. Health care rounds sometimes land toward the higher end of that range simply because the capital needed to clear a regulatory or clinical milestone is bigger, so it's worth running your own numbers with a startup valuation calculator before you set a target for how much to raise and how much of the company you're willing to give up for it.
How much money is actually flowing into Dutch health tech
Dutch healthtech companies raised a combined $177 million across 10 rounds in early 2025, according to Dealroom data reported by Silicon Canals.Source That's a modest slice of the roughly €3.1 billion in venture capital Dutch startups raised in total over the same trailing period, per the State of Dutch Tech report the same article cites. The takeaway for founders: health care is a real, funded category in the Netherlands, but it's still a specialist pocket of a much bigger pool, not where most Dutch VC money is going by default. That's exactly why a targeted list of investors who actually focus on health care, rather than a generalist spray-and-pray approach, matters more here than it would in a hotter category.
How to approach health care investors in the Netherlands
Because this investor base skews toward funds rather than individuals, your outreach should look more like a targeted institutional pitch than a warm-and-friendly angel email. Lead with the clinical or scientific credibility of your team in the first two lines, not buried in an attachment. Funds evaluating health care deals are reading for domain expertise before they're reading for traction numbers, so make sure a scientific advisor or a relevant founder background is visible immediately.
Given how many of these investors are venture and private equity funds rather than solo angels, expect a slower, more structured process: an intro call, a data room request, then partner meetings, rather than a single email that closes a check. Build that timeline into your fundraising plan from the start, and keep your outreach organized with an outreach email tool so you're not losing track of who you've contacted and where each conversation stands.
Dutch health care investing runs on funds with real dry powder and a real appetite for regulatory complexity, which is good news if your startup has a credible clinical or scientific story to tell. Start with the seed-focused funds clustered around Amsterdam, be upfront about your regulatory timeline, and use a fundraising CRM to keep the longer, more structured process organized as it moves from first call to term sheet.
Health care investors
